Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03.
暂无分享,去创建一个
C. Sommer | G. Reifenberger | M. Weller | W. Wick | J. Steinbach | R. Kortmann | T. Hundsberger | M. Bamberg | R. Meyermann | U. Herrlinger | Simon Loeser | J. Rieger | B. Blaschke | D. Koch | Ta-Chih Tan | S. Loeser | Britta Blaschke
[1] A. Omuro,et al. Salvage temozolomide for prior temozolomide responders , 2005, Cancer.
[2] K. Hoang-Xuan,et al. Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] V. Rigau,et al. A dose finding phase I study of temozolomide (TMZ) and BCNU combined regimen (TEMOBIC) as a treatment of high grade glioma (HGG) in adult chemo-naïve patients , 2005 .
[4] D. Misailidou,et al. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Martin J. van den Bent,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[6] R. Mirimanoff,et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.
[7] M. Wolter,et al. Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors , 2005, International journal of cancer.
[8] J. Raizer,et al. Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy. , 2004, Neuro-oncology.
[9] J. Dichgans,et al. One week on/one week off: A novel active regimen of temozolomide for recurrent glioblastoma , 2004, Neurology.
[10] Susan M. Chang,et al. Phase II study of neoadjuvant 1, 3‐bis (2‐chloroethyl)‐1‐nitrosourea and temozolomide for newly diagnosed anaplastic glioma , 2004, Cancer.
[11] G. Weiss,et al. A Randomized Phase I and Pharmacological Trial of Sequences of 1,3-bis(2-Chloroethyl)-1-Nitrosourea and Temozolomide in Patients with Advanced Solid Neoplasms , 2004, Clinical Cancer Research.
[12] Susan M. Chang,et al. Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study. , 2004, Neuro-oncology.
[13] M. Weller,et al. Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] L. Stewart,et al. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials , 2002, The Lancet.
[15] Susan M. Chang,et al. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme. , 2001, International journal of radiation oncology, biology, physics.
[16] Scar,et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.
[17] M. Prados,et al. A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide: a North American Brain Tumor Consortium study. , 2000, Neuro-oncology.
[18] M J Gleason,et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] L. Deangelis,et al. Malignant glioma: Who benefits from adjuvant chemotherapy? , 1998, Annals of neurology.
[20] W. Curran,et al. Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. , 1998, International journal of radiation oncology, biology, physics.
[21] J. Herman,et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[22] G. Reifenberger,et al. Analysis of p53 Mutation and Epidermal Growth Factor Receptor Amplification in Recurrent Gliomas with Malignant Progression , 1996, Journal of neuropathology and experimental neurology.
[23] D. Nelson,et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. , 1993, Journal of the National Cancer Institute.
[24] T. Cascino,et al. Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.